JP2019534057A - 標的指向性にされた蛍光分子を用いる神経のその場での視覚化のためのシステムおよび方法 - Google Patents
標的指向性にされた蛍光分子を用いる神経のその場での視覚化のためのシステムおよび方法 Download PDFInfo
- Publication number
- JP2019534057A JP2019534057A JP2019510425A JP2019510425A JP2019534057A JP 2019534057 A JP2019534057 A JP 2019534057A JP 2019510425 A JP2019510425 A JP 2019510425A JP 2019510425 A JP2019510425 A JP 2019510425A JP 2019534057 A JP2019534057 A JP 2019534057A
- Authority
- JP
- Japan
- Prior art keywords
- target site
- patient
- fluorescent molecules
- fluorescent
- nerve
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 67
- 238000012800 visualization Methods 0.000 title claims abstract description 18
- 238000011065 in-situ storage Methods 0.000 title claims abstract description 12
- 210000005036 nerve Anatomy 0.000 title claims description 19
- 238000003384 imaging method Methods 0.000 claims abstract description 31
- 238000001514 detection method Methods 0.000 claims abstract description 20
- 230000007246 mechanism Effects 0.000 claims abstract description 16
- 239000000835 fiber Substances 0.000 claims description 45
- 239000007788 liquid Substances 0.000 claims description 13
- 210000004027 cell Anatomy 0.000 claims description 9
- 239000007850 fluorescent dye Substances 0.000 claims description 9
- 210000004126 nerve fiber Anatomy 0.000 claims description 8
- 210000002569 neuron Anatomy 0.000 claims description 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 7
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 5
- 108091006047 fluorescent proteins Proteins 0.000 claims description 5
- 102000034287 fluorescent proteins Human genes 0.000 claims description 5
- 238000012285 ultrasound imaging Methods 0.000 claims description 5
- 210000000578 peripheral nerve Anatomy 0.000 claims description 4
- 239000013307 optical fiber Substances 0.000 description 24
- 238000010586 diagram Methods 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- 239000002245 particle Substances 0.000 description 10
- 239000000523 sample Substances 0.000 description 10
- 239000008194 pharmaceutical composition Substances 0.000 description 9
- 230000008685 targeting Effects 0.000 description 9
- 238000005253 cladding Methods 0.000 description 8
- 238000002059 diagnostic imaging Methods 0.000 description 8
- 238000002604 ultrasonography Methods 0.000 description 8
- 238000009472 formulation Methods 0.000 description 7
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000004891 communication Methods 0.000 description 5
- 239000006185 dispersion Substances 0.000 description 5
- 239000000975 dye Substances 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 238000002591 computed tomography Methods 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000013308 plastic optical fiber Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- QGKMIGUHVLGJBR-UHFFFAOYSA-M (4z)-1-(3-methylbutyl)-4-[[1-(3-methylbutyl)quinolin-1-ium-4-yl]methylidene]quinoline;iodide Chemical compound [I-].C12=CC=CC=C2N(CCC(C)C)C=CC1=CC1=CC=[N+](CCC(C)C)C2=CC=CC=C12 QGKMIGUHVLGJBR-UHFFFAOYSA-M 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 3
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 210000003484 anatomy Anatomy 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 230000005284 excitation Effects 0.000 description 3
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 3
- -1 for example Substances 0.000 description 3
- 239000005090 green fluorescent protein Substances 0.000 description 3
- 238000002595 magnetic resonance imaging Methods 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 230000008054 signal transmission Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 229920003169 water-soluble polymer Polymers 0.000 description 3
- MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 2
- IANQTJSKSUMEQM-UHFFFAOYSA-N 1-benzofuran Chemical compound C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 description 2
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 2
- KAKZBPTYRLMSJV-UHFFFAOYSA-N Butadiene Chemical compound C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000000560 biocompatible material Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 239000008177 pharmaceutical agent Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- BBEAQIROQSPTKN-UHFFFAOYSA-N pyrene Chemical compound C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C43 BBEAQIROQSPTKN-UHFFFAOYSA-N 0.000 description 2
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 2
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 2
- 239000001022 rhodamine dye Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- YMHOBZXQZVXHBM-UHFFFAOYSA-N 2,5-dimethoxy-4-bromophenethylamine Chemical compound COC1=CC(CCN)=C(OC)C=C1Br YMHOBZXQZVXHBM-UHFFFAOYSA-N 0.000 description 1
- OBYNJKLOYWCXEP-UHFFFAOYSA-N 2-[3-(dimethylamino)-6-dimethylazaniumylidenexanthen-9-yl]-4-isothiocyanatobenzoate Chemical compound C=12C=CC(=[N+](C)C)C=C2OC2=CC(N(C)C)=CC=C2C=1C1=CC(N=C=S)=CC=C1C([O-])=O OBYNJKLOYWCXEP-UHFFFAOYSA-N 0.000 description 1
- KYGSXEYUWRFVNY-UHFFFAOYSA-N 2-pyran-2-ylidenepropanedinitrile Chemical compound N#CC(C#N)=C1OC=CC=C1 KYGSXEYUWRFVNY-UHFFFAOYSA-N 0.000 description 1
- AUUIARVPJHGTSA-UHFFFAOYSA-N 3-(aminomethyl)chromen-2-one Chemical class C1=CC=C2OC(=O)C(CN)=CC2=C1 AUUIARVPJHGTSA-UHFFFAOYSA-N 0.000 description 1
- NJYVEMPWNAYQQN-UHFFFAOYSA-N 5-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C21OC(=O)C1=CC(C(=O)O)=CC=C21 NJYVEMPWNAYQQN-UHFFFAOYSA-N 0.000 description 1
- YMZMTOFQCVHHFB-UHFFFAOYSA-N 5-carboxytetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=C(C(O)=O)C=C1C([O-])=O YMZMTOFQCVHHFB-UHFFFAOYSA-N 0.000 description 1
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 1
- CJIJXIFQYOPWTF-UHFFFAOYSA-N 7-hydroxycoumarin Natural products O1C(=O)C=CC2=CC(O)=CC=C21 CJIJXIFQYOPWTF-UHFFFAOYSA-N 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- 108091005944 Cerulean Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 108091005960 Citrine Proteins 0.000 description 1
- 108091005943 CyPet Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 108091005941 EBFP Proteins 0.000 description 1
- 108091005947 EBFP2 Proteins 0.000 description 1
- 108091005942 ECFP Proteins 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004721 Polyphenylene oxide Chemical group 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 description 1
- 241000545067 Venus Species 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M acrylate group Chemical group C(C=C)(=O)[O-] NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 150000004982 aromatic amines Chemical class 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000004323 axial length Effects 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000005387 chalcogenide glass Substances 0.000 description 1
- 150000004697 chelate complex Chemical class 0.000 description 1
- 239000011035 citrine Substances 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 230000001427 coherent effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 150000004775 coumarins Chemical class 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000001400 expression cloning Methods 0.000 description 1
- GVEPBJHOBDJJJI-UHFFFAOYSA-N fluoranthrene Natural products C1=CC(C2=CC=CC=C22)=C3C2=CC=CC3=C1 GVEPBJHOBDJJJI-UHFFFAOYSA-N 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 239000005372 fluoroaluminate glass Substances 0.000 description 1
- 239000005386 fluorozirconate glass Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052747 lanthanoid Inorganic materials 0.000 description 1
- 150000002602 lanthanoids Chemical class 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- QDLAGTHXVHQKRE-UHFFFAOYSA-N lichenxanthone Natural products COC1=CC(O)=C2C(=O)C3=C(C)C=C(OC)C=C3OC2=C1 QDLAGTHXVHQKRE-UHFFFAOYSA-N 0.000 description 1
- 108091005949 mKalama1 Proteins 0.000 description 1
- 239000000696 magnetic material Substances 0.000 description 1
- 239000002122 magnetic nanoparticle Substances 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000002991 molded plastic Substances 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- IEQIEDJGQAUEQZ-UHFFFAOYSA-N phthalocyanine Chemical compound N1C(N=C2C3=CC=CC=C3C(N=C3C4=CC=CC=C4C(=N4)N3)=N2)=C(C=CC=C2)C2=C1N=C1C2=CC=CC=C2C4=N1 IEQIEDJGQAUEQZ-UHFFFAOYSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 229920000962 poly(amidoamine) Polymers 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920000570 polyether Chemical group 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 150000004032 porphyrins Chemical class 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- WVIICGIFSIBFOG-UHFFFAOYSA-N pyrylium Chemical compound C1=CC=[O+]C=C1 WVIICGIFSIBFOG-UHFFFAOYSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 229910052761 rare earth metal Inorganic materials 0.000 description 1
- MUSLHCJRTRQOSP-UHFFFAOYSA-N rhodamine 101 Chemical compound [O-]C(=O)C1=CC=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MUSLHCJRTRQOSP-UHFFFAOYSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000008137 solubility enhancer Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical compound C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 description 1
- 235000021286 stilbenes Nutrition 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 125000003698 tetramethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000010396 two-hybrid screening Methods 0.000 description 1
- ORHBXUUXSCNDEV-UHFFFAOYSA-N umbelliferone Chemical compound C1=CC(=O)OC2=CC(O)=CC=C21 ORHBXUUXSCNDEV-UHFFFAOYSA-N 0.000 description 1
- HFTAFOQKODTIJY-UHFFFAOYSA-N umbelliferone Natural products Cc1cc2C=CC(=O)Oc2cc1OCC=CC(C)(C)O HFTAFOQKODTIJY-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 150000003732 xanthenes Chemical class 0.000 description 1
- 108091005957 yellow fluorescent proteins Proteins 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
- A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
- A61K49/0097—Cells, viruses, ghosts, red blood cells, viral vectors, used for imaging or diagnosis in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
- A61B5/0071—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence by measuring fluorescence emission
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
- A61B5/055—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/40—Detecting, measuring or recording for evaluating the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/44—Detecting, measuring or recording for evaluating the integumentary system, e.g. skin, hair or nails
- A61B5/441—Skin evaluation, e.g. for skin disorder diagnosis
- A61B5/444—Evaluating skin marks, e.g. mole, nevi, tumour, scar
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4821—Determining level or depth of anaesthesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
- A61B6/02—Arrangements for diagnosis sequentially in different planes; Stereoscopic radiation diagnosis
- A61B6/03—Computed tomography [CT]
- A61B6/032—Transmission computed tomography [CT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
- A61B6/12—Arrangements for detecting or locating foreign bodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B8/00—Diagnosis using ultrasonic, sonic or infrasonic waves
- A61B8/08—Detecting organic movements or changes, e.g. tumours, cysts, swellings
- A61B8/0833—Detecting organic movements or changes, e.g. tumours, cysts, swellings involving detecting or locating foreign bodies or organic structures
- A61B8/085—Detecting organic movements or changes, e.g. tumours, cysts, swellings involving detecting or locating foreign bodies or organic structures for locating body or organic structures, e.g. tumours, calculi, blood vessels, nodules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/01—Introducing, guiding, advancing, emplacing or holding catheters
- A61M25/06—Body-piercing guide needles or the like
- A61M25/0606—"Over-the-needle" catheter assemblies, e.g. I.V. catheters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/40—Detecting, measuring or recording for evaluating the nervous system
- A61B5/4029—Detecting, measuring or recording for evaluating the nervous system for evaluating the peripheral nervous systems
- A61B5/4041—Evaluating nerves condition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B8/00—Diagnosis using ultrasonic, sonic or infrasonic waves
- A61B8/44—Constructional features of the ultrasonic, sonic or infrasonic diagnostic device
- A61B8/4405—Device being mounted on a trolley
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B8/00—Diagnosis using ultrasonic, sonic or infrasonic waves
- A61B8/48—Diagnostic techniques
- A61B8/481—Diagnostic techniques involving the use of contrast agent, e.g. microbubbles introduced into the bloodstream
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/645—Specially adapted constructive features of fluorimeters
- G01N21/6456—Spatial resolved fluorescence measurements; Imaging
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pathology (AREA)
- Medical Informatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Hematology (AREA)
- High Energy & Nuclear Physics (AREA)
- Anesthesiology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Optics & Photonics (AREA)
- Vascular Medicine (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Theoretical Computer Science (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Physiology (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
Abstract
Description
Claims (20)
- 医療処置中に患者内の標的部位のその場での視覚化を実現するためのシステムであって、
前記患者内の前記標的部位の1つ以上の位置を選択的に標的とし、それに結合するように構成される複数の蛍光分子と、
前記複数の蛍光分子を前記患者のなかの前記標的部位に向かって送達するための送達メカニズムと、
前記標的部位に関する情報を含む検出可能な信号を生成し、前記検出可能な信号を画像化システムに送信するように構成された検出装置とを備え、
前記複数の蛍光分子は、前記患者の皮膚を通して観察した前記標的部位のその場での視覚化を実現することを特徴とするシステム。 - 請求項1のシステムにおいて、
前記検出装置は、エミッタおよびレシーバとを備える少なくとも1つのセンサを更に備えることを特徴とするシステム。 - 請求項1または2のシステムにおいて、
前記少なくとも1つのセンサは、光ファイバセンサを含むことを特徴とするシステム。 - 請求項1〜3のいずれか一項に記載のシステムにおいて、
前記複数の蛍光分子の各々は、約1nm〜約100nmの直径を有することを特徴とするシステム。 - 請求項1〜4のいずれか一項に記載のシステムにおいて、
前記複数の蛍光分子は、約1000〜約100万の蛍光分子の量で液体媒体中に懸濁されることを特徴とするシステム。 - 請求項5のシステムにおいて、
前記液体媒体は、前記送達メカニズムを介して、複数のファージを介して前記標的部位に送達されることを特徴とするシステム。 - 請求項1〜6のいずれか一項に記載のシステムにおいて、
前記送達メカニズムは、ニードルまたは注射器の少なくとも一方を含むことを特徴とするシステム。 - 請求項1〜7のいずれか一項に記載のシステムにおいて、
前記複数の蛍光分子の各々は、蛍光部分、蛍光タンパク質、ペプチド、または蛍光染料のうちの少なくとも1つを含むことを特徴とするシステム。 - 請求項1〜8のいずれか一項に記載のシステムにおいて、
前記複数の蛍光分子は、前記患者内に拡散する前に、所定の滞留時間の間、前記標的部位の1つ以上の位置に一時的に結合し、前記複数の蛍光分子の前記所定の滞留時間は約1日〜約2日を含むことを特徴とするシステム。 - 請求項1〜9のいずれか一項に記載のシステムにおいて、
前記患者の前記標的部位は、神経細胞、癌細胞、神経鞘、神経束、または神経線維のうちの少なくとも1つを含むことを特徴とするシステム。 - 請求項1〜10のいずれか一項に記載のシステムにおいて、
前記医療処置は、末梢神経ブロック処置を含むことを特徴とするシステム。 - 請求項1〜11のいずれか一項に記載のシステムにおいて、
前記画像化システムは、CTスキャナ、MRIスキャナ、または超音波画像化システムのうちの少なくとも1つを含み、前記画像化システムは、前記標的部位を表示するためのディスプレイを備え、
前記複数の蛍光分子は、前記ディスプレイによって観察するときの前記標的部位の視覚化を音響的に実現することを特徴とするシステム。 - 医療処置中に患者の皮膚を通して患者内の標的部位を検出する方法であって、
複数の蛍光分子を、送達メカニズムを介して、前記患者のなかの前記標的部位に向けて送達するステップと、
前記複数の蛍光分子が選択的に前記標的部位を標的とし、前記標的部位に結合することを可能とするステップと、
前記複数の蛍光分子が前記標的部位に結合したら前記患者の前記皮膚を通して前記患者の前記標的部位を観察するステップとを含むことを特徴とする方法。 - 請求項13に記載の方法であって、
前記標的部位に向けて送達するステップが、
前記複数の蛍光分子を液体媒体中に懸濁し、前記液体媒体を、複数のファージを介して前記標的部位に送達するステップを含むことを特徴とする方法。 - 請求項13または14に記載の方法であって、
前記医療処置の関数として、前記患者に送達される前記複数の蛍光分子の量を調整するステップを更に含むことを特徴とする方法。 - 請求項13〜15のいずれか一項に記載の方法において、
前記標的部位に関する情報を含む検出可能な信号を生成し、前記検出可能な信号を画像化システムに送信する検出装置を介して、前記患者の前記皮膚を通して前記患者の前記標的部位を観察するステップを更に含むことを特徴とする方法。 - 請求項16に記載の方法であって、
前記検出装置は、エミッタおよびレシーバとを備える少なくとも1つのセンサを更に備えることを特徴とする方法。 - 請求項13〜17のいずれか一項に記載の方法において、
前記複数の蛍光分子の各々は、蛍光部分、蛍光タンパク質、ペプチド、または蛍光染料のうちの少なくとも1つを含むことを特徴とする方法。 - 請求項13〜18のいずれか一項に記載の方法において、
前記患者の前記標的部位は、神経細胞、癌細胞、神経鞘、神経束、または神経線維のうちの少なくとも1つを含み、前記医療処置は、末梢神経ブロック処置を含むことを特徴とする方法。 - 請求項16または17に記載の方法において、
前記画像化システムは、CTスキャナ、MRIスキャナ、または超音波画像化システムのうちの少なくとも1つを含み、前記画像化システムは、前記標的部位を観察するためのディスプレイを備え、
前記複数の蛍光分子は、前記ディスプレイによって観察するときに前記標的部位の視覚化を音響的に実現することを特徴とする方法。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2016/051820 WO2018052419A1 (en) | 2016-09-15 | 2016-09-15 | System and method for in situ visualization of nerves using targeted fluorescent molecules |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2019534057A true JP2019534057A (ja) | 2019-11-28 |
Family
ID=57083357
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019510425A Pending JP2019534057A (ja) | 2016-09-15 | 2016-09-15 | 標的指向性にされた蛍光分子を用いる神経のその場での視覚化のためのシステムおよび方法 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20190357772A1 (ja) |
EP (1) | EP3512568A1 (ja) |
JP (1) | JP2019534057A (ja) |
KR (1) | KR20190049729A (ja) |
AU (1) | AU2016423159A1 (ja) |
MX (1) | MX2019002443A (ja) |
WO (1) | WO2018052419A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022201532A1 (ja) * | 2021-03-26 | 2022-09-29 | 日本電気株式会社 | 可搬型装置、光ファイバセンシングシステム及び解析方法 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6167297A (en) * | 1999-05-05 | 2000-12-26 | Benaron; David A. | Detecting, localizing, and targeting internal sites in vivo using optical contrast agents |
WO2006009910A2 (en) * | 2004-06-17 | 2006-01-26 | The Regents Of The University Of California | Time-resolved optometric fluorescence detection for skin diagnostics |
GB0519391D0 (en) * | 2005-09-22 | 2005-11-02 | Aion Diagnostics Ltd | Imaging agents |
WO2007109364A2 (en) * | 2006-03-20 | 2007-09-27 | The General Hospital Corporation | Intramolecularly quenched fluorochrome conjugates and methods of use |
WO2011038043A1 (en) * | 2009-09-22 | 2011-03-31 | Targeson, Inc. | Optical imaging contrast agents and uses therof |
WO2014127145A1 (en) * | 2013-02-13 | 2014-08-21 | The Trustees Of Dartmouth College | Method and apparatus for medical imaging using differencing of multiple fluorophores |
WO2013109957A1 (en) * | 2012-01-18 | 2013-07-25 | University Of Utah Research Foundation | Devices and systems for fluorescence imaging of tissue |
US9968688B2 (en) * | 2014-11-12 | 2018-05-15 | Verily Life Sciences Llc | Shielded targeting agents, methods, and in vivo diagnostic system |
-
2016
- 2016-09-15 WO PCT/US2016/051820 patent/WO2018052419A1/en unknown
- 2016-09-15 JP JP2019510425A patent/JP2019534057A/ja active Pending
- 2016-09-15 KR KR1020197007205A patent/KR20190049729A/ko unknown
- 2016-09-15 US US16/331,997 patent/US20190357772A1/en not_active Abandoned
- 2016-09-15 AU AU2016423159A patent/AU2016423159A1/en not_active Abandoned
- 2016-09-15 EP EP16777831.5A patent/EP3512568A1/en not_active Withdrawn
- 2016-09-15 MX MX2019002443A patent/MX2019002443A/es unknown
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022201532A1 (ja) * | 2021-03-26 | 2022-09-29 | 日本電気株式会社 | 可搬型装置、光ファイバセンシングシステム及び解析方法 |
Also Published As
Publication number | Publication date |
---|---|
US20190357772A1 (en) | 2019-11-28 |
MX2019002443A (es) | 2019-06-17 |
KR20190049729A (ko) | 2019-05-09 |
EP3512568A1 (en) | 2019-07-24 |
WO2018052419A1 (en) | 2018-03-22 |
AU2016423159A1 (en) | 2019-03-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Liu et al. | The near-infrared-II fluorophores and advanced microscopy technologies development and application in bioimaging | |
JP6681334B2 (ja) | リアルタイムの蛍光源のマルチチャネル撮像のためのシステム、方法、および装置 | |
Liu et al. | Trends in fluorescence image-guided surgery for gliomas | |
Gioux et al. | Image-guided surgery using invisible near-infrared light: fundamentals of clinical translation | |
Li et al. | pH‐Activated Near‐Infrared Fluorescence Nanoprobe Imaging Tumors by Sensing the Acidic Microenvironment | |
EP0991429B1 (en) | Use of acousto-optical and sonoluminescence contrast agents in diagnostic methods | |
Ntziachristos et al. | Current concepts and future perspectives on surgical optical imaging in cancer | |
EP2698101A1 (en) | Mri imaging system for generating a rendered image | |
US20100215581A1 (en) | Contrast agents for detecting prostate cancer | |
AU2003298538A1 (en) | Techniques for identifying molecular structures and treating cell types lining a body lumen using fluorescence | |
CN101679022A (zh) | 使用表面增强拉曼纳米粒子标记物的体内肿瘤靶向和光谱检测 | |
Kim et al. | Fluorescence molecular imaging systems for intraoperative image-guided surgery | |
Coll | Cancer optical imaging using fluorescent nanoparticles | |
Cao et al. | Fast and Accurate Imaging of Lymph Node Metastasis with Multifunctional Near‐Infrared Polymer Dots | |
Bumb et al. | Trafficking of a dual-modality magnetic resonance and fluorescence imaging superparamagnetic iron oxide-based nanoprobe to lymph nodes | |
US20120101390A1 (en) | Multi-Modal Imaging for Diagnosis of Early Stage Epithelial Cancers | |
Fan et al. | Bioluminescence imaging and two-photon microscopy guided laser ablation of GBM decreases tumor burden | |
Lee et al. | Real-time near-infrared virtual intraoperative surgical photoacoustic microscopy | |
Khondee et al. | Progress in molecular imaging in endoscopy and endomicroscopy for cancer imaging | |
D’HALLEWIN et al. | Endoscopic confocal fluorescence microscopy of normal and tumor bearing rat bladder | |
JP2019534057A (ja) | 標的指向性にされた蛍光分子を用いる神経のその場での視覚化のためのシステムおよび方法 | |
Sandoval et al. | Quantifying endocytosis in vivo using intravital two-photon microscopy | |
US20140180073A1 (en) | Portable digital imaging system for fluorescence-guided surgery | |
Kang | Preliminary pre-clinical results and overview on PET/MRI/fluorescent molecular imaging | |
EP3352854A1 (en) | Bladder temperature measurement for high intensity focused ultrasound |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A524 | Written submission of copy of amendment under section 19 (pct) |
Free format text: JAPANESE INTERMEDIATE CODE: A525 Effective date: 20190220 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190905 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200901 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20200831 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201124 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210209 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20210928 |